Results 81 to 90 of about 9,215 (199)

A highly effective bifunctional ligand for radioimmunotherapy applications

, 2011
A novel bifunctional ligand (3p-C-NETA) for antibody-targeted radioimmunotherapy of 90Y and 177Lu was efficiently synthesized via regiospecific ring opening of an aziridinium ion.
Chi Soo Kang, Thien Le, Mamta Dadwal, Anzhi Dai, Hyun A. Song, Xiang Sun, Hyun-Soon Chong, Xiaoli Lan, Hyunbeom Lee, Yunwei Chen   +9 more
core   +1 more source

Review of (90)Y-ibritumomab tiuxetan as first-line consolidation radio-immunotherapy for B-cell follicular non-Hodgkin’s lymphoma

Cancer Management and Research, 2009
Christos EmmanouilidesDepartment of Medical Oncology, Interbalkan Hospital, Thessaloniki, GreeceAbstract: Several studies have indicated that radioimmunotherapy is an effective and clinically relevant complementary therapeutic approach for patients with ...
Christos Emmanouilides
doaj  

Beta emitters rhenium‐188 and lutetium‐177 are equally effective in radioimmunotherapy of HPV‐positive experimental cervical cancer

Cancer Medicine, 2016
Cervical cancer caused by the infection with the human papillomavirus (HPV) remains the fourth leading killer of women worldwide. Therefore, more efficacious treatments are needed.
Rebecca Phaeton, Zewei Jiang, Ekaterina Revskaya, Darrell R. Fisher, Gary L. Goldberg, Ekaterina Dadachova   +5 more
doaj   +1 more source

Radioimmunotherapy: a brief overview

Biomedical Imaging and Intervention Journal, 2006
With the advent of biotechnological advances and knowledge of molecular and cellular biology, radioimmunotherapy (RIT) has become a highly promising oncologic therapeutic modality with established clinically efficacy, particularly in non-Hodgkin's lymphomas.
openaire   +2 more sources

Radioimmunotherapy for Colorectal Cancer [PDF]

Clinical Cancer Research, 2005
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for systemic antitumor therapy. Radioimmunotherapy utilizes radioisotopes conjugated to monoclonal antibodies to deliver tumoricidal radiation doses.
openaire   +2 more sources

Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

Pharmaceuticals, 2015
Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate.
Diane E. Milenic, Alfredo A. Molinolo, María S. Solivella, Eileen Banaga, Julien Torgue, Sarah Besnainou, Martin W. Brechbiel, Kwamena E. Baidoo   +7 more
doaj   +1 more source

Supplementary Figures S1-S2 from Integrin α_vβ₃-Targeted Radioimmunotherapy of Glioblastoma Multiforme

, 2008
Supplementary Figures S1-S2 from Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma ...
Cunjing Jin (2317948), Andrew J. Connolly (14974300), Fan Wang (135182), Zhaofei Liu (1583062), Andrew R. Hsu (2434423), Weibo Cai (337759), Anand Veeravagu (11599909), Victor Tse (14974303), Xiaoyuan Chen (322516), Gang Niu (133768), Kai Chen (129938), Bing Jia (460031)   +11 more
core   +1 more source

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium

Pharmaceutics, 2019
Melanoma is a cancer with increasing incidence and there is a need for alternatives to immunotherapy within effective approaches to treatment of metastatic melanoma.
Kevin J. H. Allen, Rubin Jiao, Mackenzie E. Malo, Connor Frank, Darrell R. Fisher, David Rickles, Ekaterina Dadachova   +6 more
doaj   +1 more source

Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists

, 2011
Despite approval by the Food and Drug Administration and consistent reports of the efficacy and safety of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, these therapies are infrequently used.
Buchanan, J W, Schaefer, N G, Niklaus G. Schaefer, Richard L. Wahl, Peng Huang, Julia W. Buchanan, Huang, P, Wahl, R L   +7 more
core   +1 more source

Prospects for radioimmunotherapy panaceas in gynecologic oncology

A phase 2 clinical trial of an innovative yttrium‐90 ( 90 Y)/P‐cadherin–directed radioimmunotherapy reinvigorates the notion of tumor‐directed delivery of a therapeutic radioactive payload against ovarian and other solid tumor cancers.
Chauhan, Aman, Kunos, Charles A.
core   +1 more source